1110 related articles for article (PubMed ID: 25981818)
1. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW;
Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
Xu J; Xu RH; Qin S; Pan H; Bai Y; Chi Y; Wang L; Bi F; Cheng Y; Liu T; Ma D; Shen L; Ba Y; Liang J; Wang X; Yau TCC; Ma BB; Yeh KH; Lin JK; Kappeler C; Shapiro J; Kalmus J; Li J
J Gastroenterol Hepatol; 2020 Aug; 35(8):1307-1316. PubMed ID: 31900959
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
9. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
[TBL] [Abstract][Full Text] [Related]
13. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Blay JY; Serrano C; Heinrich MC; Zalcberg J; Bauer S; Gelderblom H; Schöffski P; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Shi K; Ruiz-Soto R; George S; von Mehren M
Lancet Oncol; 2020 Jul; 21(7):923-934. PubMed ID: 32511981
[TBL] [Abstract][Full Text] [Related]
14. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A; Lonardi S; Garcia-Carbonero R; Elez E; Yoshino T; Sobrero A; Yao J; García-Alfonso P; Kocsis J; Cubillo Gracian A; Sartore-Bianchi A; Satoh T; Randrian V; Tomasek J; Chong G; Paulson AS; Masuishi T; Jones J; Csőszi T; Cremolini C; Ghiringhelli F; Shergill A; Hochster HS; Krauss J; Bassam A; Ducreux M; Elme A; Faugeras L; Kasper S; Van Cutsem E; Arnold D; Nanda S; Yang Z; Schelman WR; Kania M; Tabernero J; Eng C;
Lancet; 2023 Jul; 402(10395):41-53. PubMed ID: 37331369
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Brose MS; Nutting CM; Jarzab B; Elisei R; Siena S; Bastholt L; de la Fouchardiere C; Pacini F; Paschke R; Shong YK; Sherman SI; Smit JW; Chung J; Kappeler C; Peña C; Molnár I; Schlumberger MJ;
Lancet; 2014 Jul; 384(9940):319-28. PubMed ID: 24768112
[TBL] [Abstract][Full Text] [Related]
17. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]